Organization
Boston Pharmaceuticals
2 clinical trials
30 abstracts
Clinical trial
A Phase 2a, Randomized, Blinded, Placebo-controlled Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH)Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase 1 Study of BOS172738 in Patients With Advanced Solid Tumors With RET Gene Alterations Including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)Status: Completed, Estimated PCD: 2023-09-26
Abstract
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.Org: Children’s Hospital of Philadelphia, University of Pennsylvania, Children's Oncology Group Statistics and Data Center, University of Florida, CanSino Biologics, Dana Farber Cancer Institute, Boston, MA,
Abstract
National survey of patient perspectives on medication costs among co-pay assistance recipients with cancer.Org: University of Oklahoma Health Sciences Center, Oklahoma City, Okyo Pharma, Fox Chase Cancer Center, Philadelphia, PA,
Abstract
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC.Org: Gustave Roussy Cancer Center, Université Paris-Saclay, Villejuif, France, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN,
Abstract
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.Org: Massachusetts General Hospital, Harvard Medical School, Boston, MA, Johns Hopkins University, Baltimore, MD,
Abstract
A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186.Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,
Abstract
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.Org: Lifespan Cancer Institute, Rhode Island Hospital, Providence, RI, Women and Infants Hospital of Rhode Island, University of Illinois at Chicago,
Abstract
Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis following mismatched unrelated donor peripheral blood stem cell (PBSC) transplantation.Org: City of Hope National Medical Center, CIBMTR (Center for International Blood and Marrow Transplant Research), NMDP, Medical College of Wisconsin, Memorial Sloan Kettering Cancer Center,
Abstract
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.Org: Massachusetts General Hospital, Boston, MA, Harvard Medical School, The Ohio State University Wexner Medical Center, Columbus, OH,
Abstract
Adjunctive statistical standardization of quantitated adjuvant ER and PgR in CCTG MA.27.Org: Ontario Institute for Cancer Research, Toronto, ON, Canada, MASS General Hospital BHX-1, Mayo Clinic Department of Oncology, Progendis, Caris Life Sciences,
Abstract
Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).Org: Cancer Center, Stanford, Palo Alto, CA, Foundation Medicine, Inc., San Diego, CA, Foundation Medicine, Inc., Cambridge, MA, SUNY Upstate Medical University, Syracuse, NY, Foundation Medicine, Inc., Boston, MA,
Abstract
Unstructured EMR data hold the key to oncology studies: Methods for validating NLP-extracted phenotypes from EMR notes.Org: IQVIA, Boston Pharmaceuticals, MaaT Pharma, South Bend, Intercept Pharmaceuticals,
Abstract
Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay.Org: Precede Biosciences, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings,
Abstract
Dual targeting of αv and α5β1 integrins in triple-negative breast cancer (TNBC).Org: Tufts Medical Center/Tufts University, Boston Pharmaceuticals, MaaT Pharma, Tufts University School of Medicine,
Abstract
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.Org: School of Medicine, Zhejiang University, Hangzhou, China, Yale University, New Haven, CTI BioPharma, Keck School of Medicine of the University of Southern California,
Abstract
A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).Org: Medical Oncology Group, Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Dana-Farber Cancer Institute/Harvard Cancer Center, Boston, MA,
Abstract
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.Org: Memorial Sloan Kettering Cancer Center, New York Oncology Hematology PC, Nykode Therapeutics, Massachusetts General Hospital, Boston Pharmaceuticals,
Abstract
BOS-371, a monoclonal antibody against IL1RAP: Characterization in preclinical models of AML.Org: Boston Pharmaceuticals, GSK Research and Development Upper Providence, Collegeville, PA, Shanghai ChemPartner Co., Ltd.,
Abstract
Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.Org: Massachusetts General Hospital, Harvard Medical School, Oryzon Genomics, Cornella De Llobregat, Barcelona Clinic Liver Cancer,
Abstract
Dietary and lifestyle profiles between patients with and without cancer in the National Health Interview Survey.Org: New York Medical College - Saint Michael's Medical Center, Valhalla, NY, Harvard School of Public Health & Nutrition, Boston Pharmaceuticals, Beth Israel Deaconess Medical Center,
Abstract
The impact of portability of wearable monitoring device on study retention and participant experience in patients with unresectable stage III NSCLC treated with standard-of-care durvalumab: Learnings from the ON TRAX pilot study.Org: AstraZeneca, Gaithersburg, MD, MD Anderson Cancer Center, Current Health, Boston Pharmaceuticals,
Abstract
A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator's choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial).Org: Institut Gustave Roussy, Villejuif, France, Hospital Universitario 12 de Octubre, Madrid, Spain, Spain,
Abstract
AI-driven real-time patient identification for randomized controlled trials.Org: Mango Sciences, Inc., Boston Pharmaceuticals, Subhash Nagar, Nelamangala, Indiana University – Purdue University Indianapolis,
Abstract
Translated consent documents (CDs) and use in non-industry sponsored studies (NISS).Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, UCLA Department of Medicine, Los Angeles Medical Center, CanSino Biologics,
Abstract
Real-world treatment patterns of non-small cell lung cancer in an Indian hospital.Org: Mango Sciences, Inc., Boston Pharmaceuticals, MaaT Pharma, Subhash Nagar, Nelamangala,
Abstract
Recurrent versus non-recurrent triple negative breast cancer: An institutional study.Org: Geisinger Northeast, Wilkes Barre, PainReform, The Pennsylvania State University, State College,
Abstract
Falls and hospitalization during chemotherapy in older women with early breast cancer.Org: City of Hope National Medical Center, Duarte, CA, University of Nebraska Medical Center, Omaha NE, Neurocentria,
Abstract
Real-world evidence study of treatment patterns and outcomes following covalent BTKi discontinuation in a contemporary cohort of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients.Org: Dana-Farber Cancer Institute, Boston Pharmaceuticals, MaaT Pharma, Analysis Group, Inc., Inc.,
Abstract
Machine learning to predict future PSA in patients with prostate cancer managed with active surveillance.Org: Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge University Hospitals NHS Foundation Trust, Department of Radiology and Biomedical Imaging, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
ANALYSIS AT ONE YEAR OF AN INCEPTION COHORT OF EARLY RHEUMATOID ARTHRITIS (RA): THE SONORA STUDYOrg: Cedars Sinai Medical Center, Los Angeles, United States, University Health Network, Toronto, Canada, New England Medical Center,
Abstract
A POPULATION-BASED, PROSPECTIVE METABOLOMICS STUDY IN THE UK BIOBANK IDENTIFIES GLYCOPROTEIN ACETYLS AS A NOVEL BIOMARKER OF INCIDENT GOUTOrg: Massachusetts General Hospital, CTEU, Mongan Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, Boston Pharmaceuticals,